GlassScriptPhysician profile
Cory Thomas Rued
NPI 1720438195
$1,288.33
in general payments reported to CMS, 2019-2025
15 companies · $173 in 2025
The $173 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $124 · 2021: $252 · 2022: $159 · 2023: $153 · 2024: $118 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $443.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $301.79 | 2019-2023 | |
| Alcon Vision LLC | $262.36 | 2019-2025 | Precision 1, Precision7, Dailies |
| Johnson & Johnson Vision Care, INC. | $218.83 | 2019-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $128.81 | 2019-2021 | |
| Allergan, INC. | $78.16 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $76.50 | 2023-2025 | Xiidra, Miebo, Infuse |
| Abbvie INC. | $65.89 | 2022-2025 | Vuity, Alphagan P, Lumigan |
| Oyster Point Pharma, INC. | $42.14 | 2023-2024 | Tyrvaya, Ryzumvi |
| Horizon Therapeutics Plc | $19.30 | 2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $18.51 | 2024 | Xdemvy |
| Shire North American Group INC | $16.27 | 2019 | |
| Coopervision INC. | $16.10 | 2019 | |
| Kala Pharmaceuticals, INC. | $15.27 | 2022 | |
| Thea Pharma INC. | $14.48 | 2025 | Iyuzeh |
| Biotissue Holdings INC. | $13.92 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Rued listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.